← The library
VIP
Vasoactive Intestinal PeptideCardio/VascularEvidence grade
CMixed/unclear regulatory status
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions
Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.
PurposeImmune / Neurovascular
MechanismNeuropeptide involved in vasodilation and immune signaling
EffectsWidens blood vessels; can lower blood pressure
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published3 sourced
Clinical trialAviptadil (synthetic VIP) in COVID-19 respiratory failure
RouteIntravenous; inhaled
FrequencyIV over 12 h on days 1-3; inhaled three times daily
StartingIV 50 pmol/kg/h
EscalationIV 100, then 150 pmol/kg/h
TargetIV 150 pmol/kg/h by day 3. Inhaled: 100 mcg three times daily.
Overall result negative per community summary.
Clinical trialIntranasal VIP in CIRS (open-label, uncontrolled)
RouteIntranasal
FrequencyFour times daily
Starting50 mcg/spray
EscalationNone
Target50 mcg/spray, four times daily
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous; intranasal
FrequencySC 1-2x daily or 5x weekly; nasal 4-8 sprays/day
StartingSC 50 mcg once daily for 1-2 weeks ("conservative start")
EscalationSC 100 mcg 1-2x daily ("standard"); 200 mcg 1-2x daily ("advanced")
TargetSC 50-200 mcg per injection; "100 mcg twice daily" most discussed. Nasal about 50 mcg/spray, 4-8 sprays/day.
Cycle"Ongoing"; no cycle length given
The guide's safety monitor is lipase: "Rising lipase or belly pain means stop."
Batches on filenone
No tested batches on file.
Cautions & interactions
Complex systemic effects; medical supervision required
No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.
CV 1 of 5 — Limited direct cardiovascular evidence.